NASDAQ:ABCL AbCellera Biologics (ABCL) Stock Price, News & Analysis $4.57 +0.52 (+12.84%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$4.53 -0.04 (-0.98%) As of 09:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AbCellera Biologics Stock (NASDAQ:ABCL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AbCellera Biologics alerts:Sign Up Key Stats Today's Range$4.05▼$4.6150-Day Range$3.27▼$5.2552-Week Range$1.94▼$6.51Volume8.45 million shsAverage Volume9.72 million shsMarket Capitalization$1.40 billionP/E RatioN/ADividend YieldN/APrice Target$7.80Consensus RatingModerate Buy Company Overview AbCellera Biologics Inc. (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection. AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis. Since its founding, the company has announced collaborations with multiple global drug developers to discover antibodies for oncology, infectious diseases, autoimmune disorders and other therapeutic areas. Notably, AbCellera’s platform enabled the rapid identification of bamlanivimab, an antibody developed in collaboration with Eli Lilly for use in COVID-19 treatment. Founded in 2012 and based on research at the University of British Columbia, AbCellera is headquartered in Vancouver, Canada, and maintains additional research sites and offices in the United States and Europe. The company serves a global client base, supporting both established pharmaceutical companies and emerging biotech ventures. AbCellera’s platform has been applied to more than a dozen target programs, demonstrating flexibility across diverse biological challenges. Under the leadership of co-founder and Chief Executive Officer Carl Hansen, AbCellera has built a multidisciplinary team of immunologists, data scientists and engineers. The management team continues to advance platform innovations and expand service offerings with the goal of delivering novel antibody therapeutics to patients worldwide.AI Generated. May Contain Errors. Read More AbCellera Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreABCL MarketRank™: AbCellera Biologics scored higher than 56% of companies evaluated by MarketBeat, and ranked 427th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingAbCellera Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAbCellera Biologics has a consensus price target of $7.80, representing about 70.7% upside from its current price of $4.57.Amount of Analyst CoverageAbCellera Biologics has only been the subject of 3 research reports in the past 90 days.Read more about AbCellera Biologics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.67) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbCellera Biologics is -9.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AbCellera Biologics is -9.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbCellera Biologics has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AbCellera Biologics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted20.34% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 5.98.Change versus previous monthShort interest in AbCellera Biologics has recently decreased by 6.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbCellera Biologics does not currently pay a dividend.Dividend GrowthAbCellera Biologics does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.17 News SentimentAbCellera Biologics has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for AbCellera Biologics this week, compared to 3 articles on an average week.Search Interest37 people have searched for ABCL on MarketBeat in the last 30 days. This is an increase of 236% compared to the previous 30 days.MarketBeat Follows7 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AbCellera Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders28.40% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AbCellera Biologics' insider trading history. Receive ABCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABCL Stock News Headlines7 Healthcare AI Stocks Under $50 With Huge Upside PotentialMay 18 at 7:35 AM | 247wallst.comAbCellera Biologics (NASDAQ:ABCL) Downgraded by Wall Street Zen to "Sell"May 16, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 21 at 1:00 AM | InvestorPlace (Ad)Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14May 15, 2026 | finance.yahoo.comAbCellera Biologics Inc. 2026 Q1 - Results - Earnings Call PresentationMay 14, 2026 | seekingalpha.comAbCellera Biologics Inc. (ABCL) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 14, 2026 | seekingalpha.comAbCellera Biologics Inc (ABCL) Q1 2026 Earnings Call Highlights: Promising Advancements Amid ...May 12, 2026 | finance.yahoo.comAbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comSee More Headlines ABCL Stock Analysis - Frequently Asked Questions How have ABCL shares performed this year? AbCellera Biologics' stock was trading at $3.42 on January 1st, 2026. Since then, ABCL stock has increased by 33.6% and is now trading at $4.57. How were AbCellera Biologics' earnings last quarter? AbCellera Biologics Inc. (NASDAQ:ABCL) released its earnings results on Monday, May, 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.08. The firm had revenue of $8.32 million for the quarter, compared to the consensus estimate of $5.41 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 14.86% and a negative net margin of 181.75%. Read the conference call transcript. When did AbCellera Biologics IPO? AbCellera Biologics (ABCL) raised $423 million in an initial public offering on Friday, December 11th 2020. The company issued 24,150,000 shares at $17.00-$18.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO. Who are AbCellera Biologics' major shareholders? Top institutional shareholders of AbCellera Biologics include Bank of America Corp DE (0.98%), Renaissance Technologies LLC (0.49%), Royal Bank of Canada (0.13%) and SEB Asset Management AB (0.11%). Insiders that own company stock include Holdings Ltd Thermopylae and Andrew Booth. View institutional ownership trends. How do I buy shares of AbCellera Biologics? Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AbCellera Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that AbCellera Biologics investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), TotalEnergies (TTE) and AUO (AUOTY). Company Calendar Last Earnings5/11/2026Today5/21/2026Jefferies Global Healthcare Conference 20266/04/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, ABCL's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABCL CIK1703057 Webwww.abcellera.com Phone604-559-9005FaxN/AEmployees500Year Founded2012Price Target and Rating Average Price Target for AbCellera Biologics$7.80 High Price Target$11.00 Low Price Target$4.00 Potential Upside/Downside+70.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$146.41 million Net Margins-181.75% Pretax Margin-219.86% Return on Equity-14.86% Return on Assets-10.62% Debt Debt-to-Equity RatioN/A Current Ratio14.05 Quick Ratio14.05 Sales & Book Value Annual Sales$75.13 million Price / Sales18.58 Cash FlowN/A Price / Cash FlowN/A Book Value$3.07 per share Price / Book1.49Miscellaneous Outstanding Shares305,380,000Free Float218,649,000Market Cap$1.40 billion OptionableOptionable Beta1.02 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:ABCL) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
